Jonathan Chávez ✓

@JonathanNefro · joined 31 Jul 2017

Nefrólogo en Hospital Civil de Guadalajara y Profesor en la Escuela de Medicina de la Universidad de Guadalajara

39 302Followers

827Following

11 455Posts total

35.3KViews on collected posts

Latest posts

Jonathan Chávez ✓@JonathanNefro13 Sep

En hiperaldosteronismo primario, agregar iSGLT2 al manejo estandard, se asoció a ↓riesgo de: •↓41% mortalidad •↓19% evento cardiovascular mayor •↓42% evento renal mayor CJASN 2026 10.2215/CJN.0000001144 https://t.co/q6SwUji7mb

939 views · 27 likes · 7 reposts · 0 replies Open on X →

Jonathan Chávez ✓@JonathanNefro13 Sep

@JonathanNefro やっぱりレニン、アルドステロンは測る時間帯注意したほうがいいのかな、今はあまり気にせず測ってるけど 49 views · 0 likes · 0 reposts · 0 replies Open on X →

Jonathan Chávez ✓@JonathanNefro13 Sep

@JonathanNefro @cardiogax Hacia el mejor control de la hipertension arterial: el valor de un enfoque fisiológico guiado por el eje renina-aldosteronabMayra A. Estacio1* , Juan D. López-Ponce de León. •DOI: 10.24875/NEFRO.25000023 182 views · 2 likes · 0 reposts · 0 replies Open on X →

Jonathan Chávez ✓@JonathanNefro13 Sep

@JonathanNefro https://t.co/5ZjiXBHIzi

167 views · 0 likes · 0 reposts · 0 replies Open on X →

Jonathan Chávez ✓@JonathanNefro12 Sep

Solo el 2% de las personas con hiperaldosteronismo primario son diagnosticados. Recomiendan que todos los hipertensos y los que tengan enfermedad renal crónica merecen escrutinio. La combinación laboratorial clave: ↓renina y ↑~aldosterona JAMA 2026 https://t.co/IULoKuCWI3

5.9K views · 184 likes · 50 reposts · 3 replies Open on X →

Jonathan Chávez ✓@JonathanNefro12 Sep

Simplemente no hay evidencia para prescribir espironolactona en personas en diálisis, aquí los ensayos clínicos que no demostraron beneficio: •SPin-D❌ •MiREnDa❌ Y con más detalle👇🏻 •ALCHEMIST ❌ •ACHIEVE ❌ AJKD 2026 10.1053/j.ajkd.2026.04.020 https://t.co/mU0gbJ54Ng

5.6K views · 115 likes · 36 reposts · 0 replies Open on X →

Jonathan Chávez ✓@JonathanNefro11 Sep

Con diabetes y enfermedad renal crónica G3, los iSGLT2 (canagliflozina), comparado a placebo; se asoció a reducir los eventos cardiorrenales, independientemente del consumo de polifarmacia (>5 fármacos) PostHoc del CREDENCE NDT 2026 https://t.co/CcjpQLeGT2 https://t.co/lVwG8ri7

2.3K views · 35 likes · 8 reposts · 2 replies Open on X →

Jonathan Chávez ✓@JonathanNefro29 Mar

@JonathanNefro @DraMarili @RClaure_nefro @gmogarcia52 constancia y humildad siempre llevan a buen puerto… Que Orgullo Mi Jonathan, seguro otro de muchos en un futuro en tu carrera 300 views · 3 likes · 0 reposts · 2 replies Open on X →

Jonathan Chávez ✓@JonathanNefro28 Mar

@JonathanNefro @RClaure_nefro @gmogarcia52 👏👏👏👏 808 views · 3 likes · 0 reposts · 1 replies Open on X →

Jonathan Chávez ✓@JonathanNefro28 Mar

@JonathanNefro @ronald_nefro @RClaure_nefro @gmogarcia52 FELICITACIONES AMIGO @JonathanNefro 184 views · 4 likes · 1 reposts · 0 replies Open on X →

Jonathan Chávez ✓@JonathanNefro28 Mar

Que gran satisfacción haber contribuido en la nueva edición del iconico libro Brenner & Rector's The Kidney, 12th Edition 2026. En colaboración @RClaure_nefro y @gmogarcia52, que han influido profundamente en mi carrera profesional Ya está a la venta https://t.co/dT1HTWO7nx http

18.8K views · 450 likes · 39 reposts · 33 replies Open on X →

Against accounts of the same size

7 posts from the last 90 days, next to the 10K–100K follower range. reaches fewer people than peers of the same size.

Median views939this account1 098median for 10K–100K

Reach, %2.39%this account3.91%median for 10K–100K

Engagement, %1.96%this account1.66%median for 10K–100K

Metric	This account	Median for 10K–100K	Ratio
Median views per post	939	1 098	0.86×
Reach (views ÷ followers)	2.39%	3.91%	0.61×
Engagement rate	1.96%	1.66%	1.18×

Others in this range → Compare with another account → How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

18.8K28 Mar

184

808

30029 Mar

2.3K11 Sep

5.6K12 Sep

5.9K

16713 Sep

182

939

Last 11 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

2.77%28 Mar

2.72%

0.50%

1.67%29 Mar

1.96%11 Sep

2.69%12 Sep

4.01%

0.00%13 Sep

1.10%

0.00%

3.62%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.66%.

What the audience does

Likes71.4%823 in total

Reposts12.2%141 in total

Replies3.6%41 in total

Bookmarks12.8%148 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Latest posts

Against accounts of the same size

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Similar accounts